Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency

  • Francesca Palandri | francesca.palandri@libero.it Department of Hematology and Oncology L. e A. Seràgnoli, St. Orsola-Malpighi Hospital, University of Bologna, Italy.
  • Nicola Polverelli Department of Hematology and Oncology L. e A. Seràgnoli, St. Orsola-Malpighi Hospital, University of Bologna, Italy.
  • Francesca Lifrieri Nefrology Unit, Pierantoni Hospital, Forlì, Italy.
  • Lucia Catani Department of Hematology and Oncology L. e A. Seràgnoli, St. Orsola-Malpighi Hospital, University of Bologna, Italy.
  • Maria Benedetta Giannini Istituto Oncologico Romagnolo per la cura dei tumori, Meldola, Forlì, Italy.
  • Michele Baccarani Department of Hematology and Oncology L. e A. Seràgnoli, St. Orsola-Malpighi Hospital, University of Bologna, Italy.
  • Nicola Vianelli Department of Hematology and Oncology L. e A. Seràgnoli, St. Orsola-Malpighi Hospital, University of Bologna, Italy.

Abstract

Immunosuppressive agents are the standard therapeutic approach for immune thrombocytopenia (ITP). Their prolonged use may increase the risk of infectious complications, particularly when the patient is already at higher infectious risk. In this setting, the use of drugs with a mechanism of action alternative to immunosuppression, like thrombopoietin receptor agonists (TRAs), may find particular indication. We report the unique case of a patient with severe immunodeficiency and ITP, who experienced a serious infectious complication while on steroids treatment, and who was successfully treated with Romiplostim second- line. The present experience supports the effectiveness and safety of TRAs as early treatment of ITP patients with drug-induced immunodeficiency or with active infections.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2012-06-26
Info
Issue
Section
Case Reports
Keywords:
immune thrombocytopenia, romiplostim, TPO receptor agonist, immunodeficiency
Statistics
  • Abstract views: 2069

  • PDF: 352
  • HTML: 205
How to Cite
Palandri, F., Polverelli, N., Lifrieri, F., Catani, L., Giannini, M. B., Baccarani, M., & Vianelli, N. (2012). Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency. Hematology Reports, 4(2), e10. https://doi.org/10.4081/hr.2012.e10